Dr Kalinsky on Abemaciclib/Fulvestrant in HR+/HER2– B

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Related Keywords

Kevin Kalinsky , Glenn Family Breast Center , Division Of Medical Oncology , Breast Cancer Research , Department Of Hematology , Winship Cancer Institute Of Emory University , Emory University School Of Medicine , Medical Oncology , Emory University School , Rand Glenn Family Chair , Breast Medical Oncology , Winship Cancer Institute , Emory University ,